Ruti Aga's six-year ban: four of those years belong to a forged prescription

The prescription was written on an old pad from a clinic. The signature belonged to a family member with no medical registration number. When the Athletics Integrity Unit (AIU) called to verify, the clinic gave three clean answers: we did not issue this document; that person has never appeared on our staff list; and the pad in question had been void for years. Three answers. Six years of ineligibility. Ruti Aga, 32, the Ethiopian marathon runner who won the 2026 Tokyo Marathon and finished runner-up at three World Marathon Majors, has been banned for six years running from 10 September. Two years for the presence of a prohibited substance in her sample. Four years for tampering. Most of the time hanging over her belongs to a piece of paper. Aga's career sits in the elite tier of distance running: one major title, three major podium finishes, a peak window stretching across 2026 to 2026. For a female marathoner, 32 sits inside the peak, not past it; the competitive window for women routinely extends to 35 and beyond. The sanction landed at the point of maximum sporting and commercial value rather than during a decline. In March she won a half marathon in China. No finishing time was published. Her sample at that race returned an adverse finding for methylprednisolone. She explained it as treatment for a knee injury. Then the paperwork surfaced. One detail deserves precision, because much of the reporting handled it carelessly: methylprednisolone is a synthetic glucocorticoid, a corticosteroid, and categorically different from an anabolic steroid. It sits in WADA class S9, prohibited in-competition only, and is classified as a Specified Substance — a category the rules acknowledge as more plausibly linked to inadvertent or therapeutic use. Against an anabolic steroid, its baseline sanction is substantially lighter. That is why the first half of the ban stopped at two years. The second half is where the case turns. Under the World Anti-Doping Code, tampering during results management is an independent violation carrying a four-year baseline, and multiple violations are served consecutively rather than concurrently. Two plus four equals six. The AIU did not come down hard because of the substance; it came down hard because of the document. The evidentiary chain is sealed tight enough to leave almost no room for argument. The clinic denied issuing the prescription. The professional registry confirmed the signatory held no licence. The former workplace confirmed the person had never been on staff. Three independent sources, three identical conclusions. AIU verification now walks straight into the clinic instead of reading whatever paperwork is filed, and that shift is what has made this genre of forgery close to untenable. I heard stories about prescription pads like that one in a dressing-room conversation years ago. Now I tell them back through the case file. The 2026 shutdown closed the tracks. I opened Excel and spent nine months re-watching 214 matches from the women's U-20 World Cup. That habit taught me one thing: the deviant detail always lives in the appendix, never in the headline. In the Aga case, the appendix is the pad. The part worth writing about sits outside the ban itself. If the knee injection was genuinely therapeutic, a lawful route existed: apply for a TUE, prospectively or retroactively, and disclose the route and timing transparently. An honest injury case, properly declared, could plausibly have ended with no violation at all, or a far lighter outcome. Instead, someone in her inner circle chose to invent a clinic that did not exist. Ethiopians do not dope more than anyone else. They are abandoned at the paperwork stage. The distance between those two sentences is the whole problem. The East African road circuit runs an extraordinarily sophisticated selection, coaching and nutrition system, while the medical and legal support wrapped around the athlete is inversely thin. A relative, an old pad, an invented clinic name: this is not a sophisticated doping operation, it is the panic of someone with nobody advising them. On the roads themselves, the ban barely registers. Ethiopia's bench is deep enough that the absence of one major runner-up is absorbed in silence. What disappears sits elsewhere: the Chinese half marathon result is almost certainly annulled along with its prize money, major invitations evaporate, and the appearance-fee income stream — the lifeblood of a professional distance runner — closes at the same moment. The Chinese road circuit imports East African athletes on appearance fees, and races of that profile tend to carry thinner testing density than a major. This case inadvertently exposes the weak point in that supply chain. Based on my experience following the major marathons over the past five years, cases of this shape are rarely stories about substances. They are stories about infrastructure. A 32-year-old is suspended until 38. Returning to the top after six years away from competition is something women's marathon running almost never produces, even with the physical window still open. What I want to see after this case is not a harsher sanction. I want national federations and training groups to have someone on hand who knows how to file a TUE, and who understands that telling the truth is vastly cheaper than forging it. If an old prescription pad can erase six years of a career, is the first thing to build legal support for the runner, or one more layer of verification?